RhoGTPases in human immunodeficiency, hematopoiesis and malignancies

David A. Williams - Dana Farber Cancer Institute

Mar, 18 2014
11:00 DKFZ Main Auditorium

Host: M. Milsom

Biosketch David A. Williams
Dr. Williams is the Chief of Hematology/Oncology and Director of Translational Research at Boston Children’s Hospital and Associate Chairman, Department of Pediatric Oncology at Dana-Farber Cancer Institute. He is Director of the Pediatric Hematology/Oncology Fellowship Training Program at BCH/DFCI. His laboratory has been continuously NIH funded since 1986. He has trained over 45 fellows and post-doctoral fellows and numerous residents and medical students in my laboratory, the majority of which are still in academic medicine. He is a member of the Institute of Medicine of the National Academy of Sciences. He has published over 250 peer-reviewed manuscripts and textbook chapters. He formerly served on the NIH Recombinant DNA Advisory Committee and Gene Therapy Safety Assessment Board. He is actively involved in gene therapy trials for immunodeficiency and neurological genetic diseases and has been the investigator, co-investigator or sponsor (IND holder) of four previous gene therapy trials and is sponsor or investigator of three current trials. He has recently served as a councilor for the American Society of Hematology (ASH) and served on the Joint Oversight Committee of ASH/European Hematology Association Translational Research Training in Hematology. He is currently President-elect of ASH. He served as the Editor-In-Chief of Molecular Therapy from 2004-2009. He is co-founder of the Transatlantic Gene Therapy Consortium and the North American Pediatric Aplastic Anemia Consortium. His basic research has focused on hematopoietic stem cell biology, including genetic diseases of the blood and specifically molecular and biochemical analysis of the interaction between hematopoietic stem cells and the bone marrow supporting environment.

to top
powered by webEdition CMS